



an Open Access Journal by MDPI

Mesenchymal Stem Cells in Regenerative Medicine and Immunomodulation

Guest Editors:

Dr. Biancamaria Longoni

Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy

Dr. Serena Barachini

Laboratory of Hematology, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy

Dr. Hiroshi Wakao

Division of Host Defense, Center for Frontier Medicine, Dokkyo Medical University, Mibu 321-0293, Japan

Deadline for manuscript submissions:

closed (31 August 2023)

Message from the Guest Editors

Mesenchymal stem cells (MSCs) represent a heterogeneous population of adult, fibroblast-like, multipotent cells. MSCs have drawn much attention in the field of regenerative medicine over the last decade. Due to their immunomodulatory properties, they are now considered an extraordinary opportunity for multifunctional therapeutic approaches. Since these cells are "immunoprivileged," they may be the first cell type able to be used as an "off-the-shelf" therapeutic product. It has been demonstrated that cultured MSCs have the ability, upon migration, to engraft into healthy as well as injured tissue and can differentiate into several cell types in vivo, which makes MSCs an ideal tool for regenerative therapy in different disease types.

New observations and reviews of MSCs' immunomodulatory properties and potential mechanisms, as well as their effects on immunomodulation-mediated disease therapies and tissue regeneration, will be of invaluable interest to readers for the future development of MSC-based clinical applications.



mdpi.com/si/167588



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI